Today we’re thrilled to host Ron Alfa, co-founder and CEO of Noetik. Noetik is building an AI-native platform for cancer biology, generating large-scale human data to train biological foundation models that both predict patient responses to therapy and uncover new drug targets and treatment opportunities. Most recently, Noetik signed a $50 million licensing agreement with GSK, giving GSK access to Noetik’s virtual cell foundation models, along with one of the largest multimodal spatial oncology datasets assembled to date.
In this episode, we discuss Ron’s journey to founding Noetik, why building truly useful models of biology requires large-scale, multimodal human data, and how biological foundation models can transform precision oncology. We also explore what it takes to build an AI-native biotech company, lessons from partnering with pharma, the future of drug discovery, and the path toward bringing more personalized cancer treatment to every patient.
Podden och tillhörande omslagsbild på den här sidan tillhör
Pear VC. Innehållet i podden är skapat av Pear VC och inte av,
eller tillsammans med, Poddtoppen.
